News | August 26, 2021
Strong show in domestic formulations business by Indian pharma in Q1FY22: Ind-Ra
Domestic business was up 41.9% YoY and 27.7% QoQ
Domestic business was up 41.9% YoY and 27.7% QoQ
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
Anti-malaria API facility will be operational in 15-18 months
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg
It is part of the company’s pain/analgesics portfolio of OTC products
The govt has rolled out three schemes for promoting the manufacture of API
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
Subscribe To Our Newsletter & Stay Updated
